Response to Arendt‐Nielsen et al. (Methodology considerations for the paper by Horsted et al., 2023)

Leutscher, Peter Derek Christian; Hesthaven, Karoline Lichon; Hosted, Tina

doi:10.1002/ejp.2113

Cited by 1 publication

(2 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether or not this effect is within or beyond the expected magnitude of placebo analgesia has recently been under debate. 1,17,21 Doses of the cannabis major constituents' THC and CBD vary considerably between the cohorts. In the Haroutounian study, for example, 16 mean calculated cannabis daily THC dosage used (primarily by inflorescence) was 144 mg, which is 7 times higher than the dose used in the current cohort.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?

Pud,

Aamar,

Schiff-Keren

et al. 2024

PR9

View full text Add to dashboard Cite

Introduction: The use of medicinal cannabis for managing pain expands, although its efficacy and safety have not been fully established through randomized controlled trials. Objectives: This structured, prospective questionnaire-based cohort was aimed to assess long-term effectiveness and safety of cannabis oil extracts in patients with chronic pain. Methods: Adult Israeli patients licensed to use cannabis oil extracts for chronic pain were followed prospectively for 6 months. The primary outcome measure was change from baseline in average weekly pain intensity, and secondary outcomes were changes in related symptoms and quality of life, recorded before treatment initiation and 1, 3, and 6 months thereafter. Generalized linear mixed model was used to analyze changes over time. In addition, “responders” (≥30% reduction in weekly pain at any time point) were identified. Results: The study included 218 patients at baseline, and 188, 154, and 131 at 1, 3, and 6 months, respectively. At 6 months, the mean daily doses of cannabidiol and Δ9-tetrahydrocannabinol were 22.4 ± 24.0 mg and 20.8 ± 30.1 mg, respectively. Pain decreased from 7.9 ± 1.7 at baseline to 6.6 ± 2.2 at 6 months (F(3,450) = 26.22, P < 0.0001). Most secondary parameters also significantly improved. Of the 218 participants, 24% were “responders” but could not be identified by baseline parameters. “Responders” exhibited higher improvement in secondary outcomes. Adverse events were common but mostly nonserious. Conclusion: This prospective cohort demonstrated a modest overall long-term improvement in chronic pain and related symptoms and a reasonable safety profile with the use of relatively low doses of individually titrated Δ9-tetrahydrocannabinol and cannabidiol.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Whether or not this effect is within or beyond the expected magnitude of placebo analgesia has recently been under debate. 1 , 17 , 21 …”

Section: Discussionmentioning

confidence: 99%

Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?

Pud,

Aamar,

Schiff-Keren

et al. 2024

PR9

View full text Add to dashboard Cite

show abstract

Response to Arendt‐Nielsen et al. (Methodology considerations for the paper by Horsted et al., 2023)

Cited by 1 publication

References 4 publications

Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?

Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?

Contact Info

Product

Resources

About